Last update 17 Jul 2024

Favezelimab/Pembrolizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
favezelimab/pembro, Mavezelimab/Pembrolizumab, Pembrolizumab/favezelimab
+ [2]
Mechanism
LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Classical Hodgkin's LymphomaPhase 3
US
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
US
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
AU
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
AU
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
BE
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
BE
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
BR
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
BR
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
FR
18 Oct 2022
Classical Hodgkin's LymphomaPhase 3
FR
18 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.